首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1746846

日本人体微生物组市场报告（按产品、应用、疾病类型和地区）2025-2033

Japan Human Microbiome Market Report by Product, Application, Disease Type, and Region 2025-2033

出版日期: 2025年06月02日 | 出版商:

IMARC | 英文 115 Pages | 商品交期: 5-7个工作天内

价格

简介目录

2024年，日本人体微生物组市场规模达2,140万美元。展望未来， IMARC Group预计到2033年，该市场规模将达到1.675亿美元，2025-2033年期间的复合年增长率（CAGR）为23.70%。生命科学和生物技术领域的许多进步，以及政府机构在升级整体生物技术基础设施方面不断增加的投资，是推动市场成长的主要动力。

人类微生物组涵盖了存在于人类集体基因组成（称为宏基因组）中的各种微生物的遗传物质。它包含多种微生物，包括细菌、真菌、原生动物、非生物病毒和各种单细胞生物。这些微生物对人体生理产生影响，并在增强或损害代谢和免疫功能方面发挥作用。它们分布在人体组织的各个角落，是医学和分析方法进步的研究对象。微生物组在益生菌、益生元、药物以及针对各种疾病（包括但不限于糖尿病、肥胖、癌症以及与代谢、胃肠系统、神经系统（中枢和外周）和自体免疫疾病相关的疾病）的诊断和治疗系统等领域都有应用。

日本人体微生物组市场趋势：

在日本市场，该产业的成长受到多个关键因素的推动。一个重要驱动因素是慢性生活方式相关疾病和微生物失衡导致的感染发病率不断上升，这一趋势在全球范围内普遍存在。此外，日本老龄人口的成长也促进了市场扩张，老年人更容易受到此类健康状况的影响。此外，市场的成长也归功于对开发更有效的人体微生物组疗法的高度重视。例如，研究人员正在配製特定的人体肠道微生物组组合，以更有效地治疗各种胃肠道疾病。新冠疫情的爆发也刺激了市场成长，因为正在进行广泛的研究，以检查肺部微生物组、评估感染严重程度以及开发合适的治疗方法和疫苗。此外，诸如针对特定目标的微生物组疗法的开发等进步正在促进市场扩张。其他推动因素包括强劲的研发活动和製药业的显着成长，尤其是在发展中经济体，所有这些都有望在未来几年推动市场向前发展。

日本人类微生物组市场细分：

产品洞察：

益生菌
益生元
诊断测试
药物
医疗食品
其他的

应用程式洞察：

疗法
诊断

疾病类型洞察：

肥胖
糖尿病
自体免疫疾病
癌症
胃肠道疾病
中枢神经系统疾病
其他的

竞争格局：

市场研究报告也对竞争格局进行了全面的分析。报告涵盖了市场结构、关键参与者定位、最佳制胜策略、竞争仪錶板和公司评估象限等竞争分析。此外，报告还提供了所有主要公司的详细资料。

本报告回答的关键问题：

日本人体微生物组市场迄今表现如何？未来几年将如何表现？
COVID-19 对日本人体微生物组市场有何影响？
日本人体微生物组市场依产品划分是怎样的？
日本人体微生物组市场根据应用如何分布？
根据疾病类型，日本人体微生物组市场是如何分類的？
日本人类微生物组市场的价值链分为哪些阶段？
日本人体微生物组的主要驱动因素和挑战是什么？
日本人类微生物组市场的结构是怎么样的？主要参与者是谁？
日本人体微生物组市场的竞争程度如何？

本报告回答的关键问题：

日本人体微生物组市场迄今表现如何？未来几年将如何表现？
COVID-19 对日本人体微生物组市场有何影响？
日本人体微生物组市场依产品划分是怎样的？
日本人体微生物组市场根据应用如何分布？
根据疾病类型，日本人体微生物组市场是如何分類的？
日本人类微生物组市场的价值链分为哪些阶段？
日本人体微生物组的主要驱动因素和挑战是什么？
日本人类微生物组市场的结构是怎么样的？主要参与者是谁？
日本人体微生物组市场的竞争程度如何？

Japan human microbiome market size reached USD 21.4 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 167.5 Million by 2033, exhibiting a growth rate (CAGR) of 23.70% during 2025-2033. Numerous advancements in the field of life science and biotechnology, along with the rising investments by government bodies in upgrading the overall biotechnology infrastructures, are primarily driving the market growth.

The human microbiome encompasses the genetic material present within a diverse array of microorganisms contained in the collective genetic makeup, known as the metagenome, of humans. It comprises a multitude of microorganisms, including bacteria, fungi, protozoans, non-living viruses, and various single-celled organisms. These microorganisms exert an influence on human physiology and play a role in either enhancing or compromising metabolic and immune functions. They are distributed throughout human tissues and are subjects of study for advancements in medicine and analytical methodologies. Microbiomes find applications in areas such as probiotics, prebiotics, pharmaceutical drugs, and diagnostic and therapeutic systems tailored to address various medical conditions, including but not limited to diabetes, obesity, cancer, as well as disorders related to metabolism, the gastrointestinal system, the nervous system (both central and peripheral), and autoimmune diseases.

Japan Human Microbiome Market Trends:

In the Japanese market context, the growth of the industry is being propelled by several key factors. One significant driver is the increasing incidence of chronic lifestyle-related diseases and infections resulting from microbial imbalances, a trend observed worldwide. Additionally, the growing elderly population in Japan, which is more susceptible to such health conditions, is contributing to market expansion. Furthermore, the market's growth is attributed to the heightened focus on developing human microbiome therapies with enhanced effectiveness. For instance, researchers are formulating specific combinations of human gut microbiomes to treat various gastrointestinal disorders more effectively. The outbreak of the COVID-19 pandemic has also spurred market growth, as extensive research is underway to examine lung microbiomes, assess infection severity, and develop suitable therapeutics and vaccines. Moreover, advancements like the creation of microbiome-based therapies tailored to specific targets are fostering market expansion. Other contributing factors include robust research and development (R&D) activities and significant growth in the pharmaceutical sector, particularly in developing economies, all of which are poised to propel the market forward in the coming years.

Japan Human Microbiome Market Segmentation:

Product Insights:

Probiotics
Prebiotics
Diagnostic Tests
Drugs
Medical Food
Others

Application Insights:

Therapeutics
Diagnostics

Disease Type Insights:

Obesity
Diabetes
Autoimmune Disorders
Cancer
Gastrointestinal Disorders
Central Nervous System Disorders
Others

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan human microbiome market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan human microbiome market?
What is the breakup of the Japan human microbiome market on the basis of product?
What is the breakup of the Japan human microbiome market on the basis of application?
What is the breakup of the Japan human microbiome market on the basis of disease type?
What are the various stages in the value chain of the Japan human microbiome market?
What are the key driving factors and challenges in the Japan human microbiome?
What is the structure of the Japan human microbiome market and who are the key players?
What is the degree of competition in the Japan human microbiome market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Human Microbiome Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Human Microbiome Market Landscape

5.1 Historical and Current Market Trends (2019-2024)
5.2 Market Forecast (2025-2033)

6 Japan Human Microbiome Market - Breakup by Product

6.1 Probiotics
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Forecast (2025-2033)
6.2 Prebiotics
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)
6.3 Diagnostic Tests
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2019-2024)
- 6.3.3 Market Forecast (2025-2033)
6.4 Drugs
- 6.4.1 Overview
- 6.4.2 Historical and Current Market Trends (2019-2024)
- 6.4.3 Market Forecast (2025-2033)
6.5 Medical Food
- 6.5.1 Overview
- 6.5.2 Historical and Current Market Trends (2019-2024)
- 6.5.3 Market Forecast (2025-2033)
6.6 Others
- 6.6.1 Historical and Current Market Trends (2019-2024)
- 6.6.2 Market Forecast (2025-2033)

7 Japan Human Microbiome Market - Breakup by Application

7.1 Therapeutics
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
7.2 Diagnostics
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Forecast (2025-2033)

8 Japan Human Microbiome Market - Breakup by Disease Type

8.1 Obesity
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2019-2024)
- 8.1.3 Market Forecast (2025-2033)
8.2 Diabetes
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2019-2024)
- 8.2.3 Market Forecast (2025-2033)
8.3 Autoimmune Disorders
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2019-2024)
- 8.3.3 Market Forecast (2025-2033)
8.4 Cancer
- 8.4.1 Overview
- 8.4.2 Historical and Current Market Trends (2019-2024)
- 8.4.3 Market Forecast (2025-2033)
8.5 Gastrointestinal Disorders
- 8.5.1 Overview
- 8.5.2 Historical and Current Market Trends (2019-2024)
- 8.5.3 Market Forecast (2025-2033)
8.6 Central Nervous System Disorders
- 8.6.1 Overview
- 8.6.2 Historical and Current Market Trends (2019-2024)
- 8.6.3 Market Forecast (2025-2033)
8.7 Others
- 8.7.1 Historical and Current Market Trends (2019-2024)
- 8.7.2 Market Forecast (2025-2033)

9 Japan Human Microbiome Market - Competitive Landscape

9.1 Overview
9.2 Market Structure
9.3 Market Player Positioning
9.4 Top Winning Strategies
9.5 Competitive Dashboard
9.6 Company Evaluation Quadrant

10 Profiles of Key Players

10.1 Company A
- 10.1.1 Business Overview
- 10.1.2 Product Portfolio
- 10.1.3 Business Strategies
- 10.1.4 SWOT Analysis
- 10.1.5 Major News and Events
10.2 Company B
- 10.2.1 Business Overview
- 10.2.2 Product Portfolio
- 10.2.3 Business Strategies
- 10.2.4 SWOT Analysis
- 10.2.5 Major News and Events
10.3 Company C
- 10.3.1 Business Overview
- 10.3.2 Product Portfolio
- 10.3.3 Business Strategies
- 10.3.4 SWOT Analysis
- 10.3.5 Major News and Events
10.4 Company D
- 10.4.1 Business Overview
- 10.4.2 Product Portfolio
- 10.4.3 Business Strategies
- 10.4.4 SWOT Analysis
- 10.4.5 Major News and Events
10.5 Company E
- 10.5.1 Business Overview
- 10.5.2 Product Portfolio
- 10.5.3 Business Strategies
- 10.5.4 SWOT Analysis
- 10.5.5 Major News and Events

11 Japan Human Microbiome Market - Industry Analysis

11.1 Drivers, Restraints, and Opportunities
- 11.1.1 Overview
- 11.1.2 Drivers
- 11.1.3 Restraints
- 11.1.4 Opportunities
11.2 Porters Five Forces Analysis
- 11.2.1 Overview
- 11.2.2 Bargaining Power of Buyers
- 11.2.3 Bargaining Power of Suppliers
- 11.2.4 Degree of Competition
- 11.2.5 Threat of New Entrants
- 11.2.6 Threat of Substitutes
11.3 Value Chain Analysis